Hi-Tech Pharmacal Financial Statements
Hi-Tech Pharmacal Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | April |
© 2009 Morningstar, Inc. Financial Data provided by
Hi-Tech Pharmacal Income Statement
| 2009 | 2008 | 2007 | |
|---|---|---|---|
| Revenue ($ mil.) | 108.7 | 62.0 | 58.9 |
| Gross Profit ($ mil.) | 51.7 | 21.5 | 23.2 |
| Operating Income ($ mil.) | 15.9 | (6.8) | (4.0) |
| Total Net Income ($ mil.) | 9.8 | (5.1) | (2.0) |
| Diluted EPS (Net Income) | 0.84 | (0.45) | (0.17) |
Hi-Tech Pharmacal Quarterly Statements
| Quarter Ending Jul 09 | Quarter Ending Apr 09 | Quarter Ending Jan 09 | |
|---|---|---|---|
| Revenue ($ mil.) | 43.5 | 38.3 | 29.4 |
| Gross Profit ($ mil.) | 26.6 | 19.9 | 13.8 |
| Operating Income ($ mil.) | -- | 7.8 | 3.5 |
| Total Net Income ($ mil.) | 8.7 | 5.1 | 2.1 |
| Diluted EPS (Net Income) | 0.73 | 0.44 | 0.18 |
Hi-Tech Pharmacal Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 1.70 | 1.15 | 7.01 |
| Price/Earnings Ratio | 13.64 | 23.98 | 25.51 |
| Price/Book Ratio | 2.37 | 1.73 | 6.74 |
| Price/Cash Flow Ratio | 27.32 | 9.29 | 43.48 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed Hi-Tech Pharmacal Financial Ratios
Hi-Tech Pharmacal Competitive Intelligence
| Mylan | Teva Pharmaceuticals USA | Watson Pharmaceuticals | |
|---|---|---|---|
| Annual Sales ($ mil.) | 5,137.6 | 0.0 | 2,535.5 |
| Employees | 15,000 | 1,025 | 5,070 |
| Market Cap ($ mil.) | 5,323.3 | -- | 3,739.6 |
Competitive Landscape
